LagoMed Oculogics™
Restoring Vision Through Regenerative Science
Vision is one of humanity’s most precious senses. As the global prevalence of dry eye disease, ocular surface disorders, and age-related eye conditions continues to rise, there is an increasing need for innovative therapies that address the underlying biological mechanisms rather than merely alleviating symptoms.
LagoMed Oculogics™ is dedicated to advancing regenerative ophthalmology by developing next-generation cell-free therapeutic platforms designed to support ocular surface healing, tissue repair, and long-term eye health.
Scientific Philosophy
The ocular surface is a highly specialized regenerative environment. When disrupted by inflammation, ageing, surgery, autoimmune disease, environmental stress, or prolonged digital screen exposure, the eye’s natural healing capacity becomes compromised.
Our research focuses on supporting these natural regenerative processes through advanced extracellular vesicle exosome-based technologies and complementary regenerative biomaterials.
Rather than replacing conventional ophthalmic care, LagoMed Oculogics™ seeks to complement existing clinical management by promoting biological repair mechanisms that support long-term ocular health.
Current Focus Areas
Future Research Pipeline
Looking ahead, LagoMed Oculogics™ aims to investigate regenerative applications in:
Clinical Translation
A cornerstone of the Oculogics™ platform is the commitment to generating robust clinical evidence. Planned initiatives include investigator-led clinical studies, real-world evidence programmes, and collaborations with academic institutions to evaluate safety, efficacy, and patient-reported outcomes.
By integrating laboratory science with clinical practice, LagoMed Oculogics™ seeks to establish new standards in regenerative ophthalmology.